Ascletis’ IND Filing for Its Third HCV Drug ASC21 Accepted by NMPA
Ascletis Pharma Inc. (1672.HK), a...
Read MoreAscletis Pharma Inc. (1672.HK), a...
Read MoreAlopecia areata is a chronic...
Read MoreMerck & Co., Inc. (MRK)...
Read MorePharmacies in the UK are...
Read MoreThe Union Cabinet chaired by...
Read MoreEdwards Lifesciences Corporation (NYSE: EW),...
Read MoreInventisBio (Shanghai) (hereinafter referred to...
Read MoreCTI BioPharma Corp. ( CTIC...
Read MoreDrug major Cipla is recalling...
Read MoreQUANTIC NANOTECH, a product division...
Read More